Contemporary aspects of using sildenafil


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Sildenafil has been thoroughly studied in 74 registered double-blind, placebo-controlled clinical trials assessing the efficacy and safety of the drug in a total of more than 16 000 men with erectile dysfunction (ED). However, practicing urologists have some questions regarding administering the drug in patients with multiple comorbidities. In this review, on a par with the now «classic» research, we outline the latest updates of meta-analyzes and comparative studies relating to the use of sildenafil in different groups of patients. We also discuss the problem of self-discontinuation of sildenafil therapy and the possible risks of using counterfeit phosphodiesterase type 5 inhibitors (PDE-5i).

Full Text

Restricted Access

About the authors

E. A Efremov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Department of Andrology and Human Reproduction

E. V Kasatonova

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Email: kasatonova@yandex.ru
Researcher at the Department of Andrology and Human Reproduction

Ya. I Mel’nik

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Department of Andrology and Human Reproduction

V. V Simakov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Department of Andrology and Human Reproduction

References

  1. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. 1996;8(2):47-52.
  2. Sharlip I.D. Opinion: No. Ten reasons that there will be no new pharmacologic therapies for erectile dysfunctionin the foreseeable future. International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology. 2015;41(5):832-834.
  3. Yuan J., Zhang R., Yang Z., Lee J., Liu Y., Tian J., Qin X., Ren Z., Ding H., Chen Q., Mao C., Tang J. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63: 902-912.
  4. Chen L., Staubli S.E., Schneider M.P., Kessels A.G., Ivic S., Bachmann L.M., Kessler T.M. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol 2015;68:674-680.
  5. Nehra A., Jackson G., Miner M., Billups K.L., Burnett A.L., Buvat J., Carson C.C., Cunningham G.R., Ganz P., Goldstein I., Guay A.T., Hackett G., Kloner R.A., Kostis J., Montorsi P., Ramsey M., Rosen R., Sadovsky R., Seftel A.D., Shabsigh R., Vlachopoulos C., Wu F.C. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87: 766-778.
  6. Prins J., Blanker M.H., Bohnen A.M., Thomas S., Bosch J.L. Prevalence of erectile dysfunction: a systematic review of population-based studies. Int J Impot Res. 2002;14:422-432.
  7. Saigal C.S., Wessells H., Pace J., Schonlau M., Wilt T.J. Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006;166:207-212.
  8. Kupelian V., Araujo A.B., Chiu G.R., Rosen R.C., McKinlay J.B. Relative contributions of modifiable risk factors to erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Prev Med. 2010;50:19-25.
  9. Laumann E.O., West S., Glasser D., Carson C., Rosen R., Kang J.H. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the Male Attitudes Regarding Sexual Health Survey. J Sex Med. 2007;4:57-65.
  10. Chew K.K., Stuckey B., Bremner A., Earle C., Jamrozik K. Male erectile dysfunction: its prevalence in Western australia and associated sociodemographic factors. J Sex Med. 2008;5:60-69.
  11. Grover S.A., Lowensteyn I., Kaouache M., Marchand S., Coupal L., DeCarolis E., Zoccoli J., Defoy I. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166:213-219.
  12. Kupelian V., Link C.L., McKinlay J.B. Association between smoking, passive smoking, and erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Eur Urol. 2007;52:416-422.
  13. Selvin E., Burnett A.L., Platz E.A. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151-157.
  14. Glasser D.B., Carson C. 3rd., Kang J.H., Laumann E.O. Prevalence of storage and voiding symptoms among men aged 40 years and older in a US population-based study: results from the Male Attitudes Regarding Sexual Health study. Int J Clin Pract. 2007;61:1294-1300.
  15. Ponholzer A., Temml C., Obermayr R., Wehrberger C., Madersbacher S. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? Eur Urol. 2005;48:512-518.
  16. Araujo A.B., Travison T.G., Ganz P., Chiu G.R., Kupelian V., Rosen R.C., Hall S.A., McKinlay J.B. Erectile dysfunction and mortality. J Sex Med. 2009;6:2445-2454.
  17. Goldstein I., Tseng L.J., Creanga D., Stecher V., Kaminetsky J.C. Efficacy and Safety of Sildenafil by Age in Men With Erectile Dysfunction. J Sex Med. 2016;13(5):852-859.
  18. Shabsigh R., Perelman M., Lue T.F., Broderick G.A., Lockhardt D. Men’s health issues: prevalence and correlates of erectile dysfunction. J Urol. 2005;174:662-667.
  19. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397-1404.
  20. Malavige L.S., Levy J.C. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6:1232-1247.
  21. Anderson R.J., Freedland K.E., Clouse R.E., Lustman P.J. The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes Care. 2001;24:1069-1078.
  22. Rendell M.S., Rajfer J., Wicker P.A., Smith M.D. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999;281(5):421-426.
  23. Balhara Y.P.S., Sarkar S., Gupta R. Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Endocrinology and Metabolism. 2015;19(4):451-461.
  24. Jackson G., Boon N., Eardley I., Kirby M., Dean J., Hackett G., Montorsi P., Montorsi F., Vlachopoulos C., Kloner R., Sharlip I., Miner M. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract. 2010;64(7):848-857.
  25. Grover S.A., Lowensteyn I., Kaouache M., Marchand S., Coupal L., DeCarolis E., Zoccoli J., Defoy I. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Inter Med. 2006;166:213-219.
  26. Cakir O., et al. The frequencies and characteristics of men receiving medical intervention for erectile dysfunction: Analysis of 6.2 million patients. //20128.
  27. Guazzi M., Tumminello G., Di Marco F., Guazzi M.D. Influences of Sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin. Pharmacol. Ther. 2004;76:371-378.
  28. Lewis G.D., Lachmann J., Camuso J., Lepore J.J., Shin J., Martinovic M.E., Systrom D.M., Bloch K.D., Semigran M.J. Sildenafil improves exercise hemodynamics and oxygen uptake in patients wth systolic heart failure. Circulation. 2007;115:59-66.
  29. Das A., Durrant D., Salloum F.N., Xi L., Kukreja R.C. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacology & therapeutics. 2015;147:12-21.
  30. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1997.
  31. Toorians A.W., Janssen E., Laan E., Gooren L.J., Giltay E.J., Oe P.L., Donker A.J., Everaerd W. Chronic kidney failure and sexual functioning: clinical status versus objectively assessed sexual response. Nephrol Dial Transplant. 1997;12:2654-2663.
  32. Rosas S.E., Joffe M., Franklin E., Strom B.L., Kotzker W., Brensinger C., Grossman E., Glasser D., Feldman H.I. Prevalence and determinants of erectile dysfunction in hemodialysis patients. Kidney Int. 2001;59:2259- 2266.
  33. Turk S., Karalezli G., Tonbul H.Z., Yildiz M., Altintepe L., Yildiz A., Yeksan M. Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2001;16:1818-1822.
  34. Navaneethan S.D., Vecchio M., Johnson D.W., Saglimbene V., Graziano G., Pellegrini F., Lucisano G., Craig J.C., Ruospo M., Gentile G., Manfreda V.M., Querques M., Stroumza P., Torok M., Celia E., Gelfman R., Ferrari J.N., Bednarek-Skublewska A., Dulawa J., Bonifati C., Hegbrant J., Wollheim C., Jannini E.A., Strippoli G.F. Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis. 2010;56:670-685.
  35. Vecchio M., Palmer S., De Berardis G., Craig J., Johnson D., Pellegrini F., Nicolucci A., Sciancalepore M., Saglimbene V., Gargano L., Bonifati C., Ruospo M., Navaneethan S.D., Montinaro V., Stroumza P., Zsom M., Torok M., Celia E., Gelfman R., Bednarek-Skublewska A., Dulawa J., Graziano G., Lucisano G., Gentile G., Ferrari J.N., Santoro A., Zucchelli A., Triolo G., Maffei S., Hegbrant J., Wollheim C., De Cosmo S., Manfreda V.M., Strippoli G.F. Collaborative Depression and Sexual Dysfunction in Hemodialysis Working Group. Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study. Nephrol Dial Transplant. 2012;27:2479-2488.
  36. Ghafari A., Farshid B., Afshari A.T., Sepehrvand N., Rikhtegar E., Ghasemi K., Hatami S. Sildenafil citrate can improve erectile dysfunction among chronic hemodialysis patients. Indian Journal of Nephrology. 2010;20(3):142-145.
  37. Seibel I., Poli De Figueiredo C.E., Telöken C., Moraes J.F. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol. 2002;13(11):2770-27705.
  38. Chen J., Mabjeesh N.J., Greenstein A., Nadu A., Matzkin H. Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol. 2001;165:819-821.
  39. Sam R., Patel P. Sildenafil in dialysis patients. Int J Artif Organs. 2006;29:264-268.
  40. Palmer B.F., Clegg D.J. Gonadal dysfunction in chronic kidney disease. Rev Endocr Metab Disord. 2016;Sep 1.
  41. Dachille G. Sexual dysfunction in patients under diaytic treatment. Minerva Urol Nefrol. 2006;58:195-200.
  42. Bellinghieri G., Santoro D., Lo Forti B., Mallamace A., De Santo R.M., Savica V. Erectile dysfunction in uremic dialysis patients: diagnostic evaluation in the sildenafil era. Am J Kidney Dis. 2001;38(4):115-117.
  43. Mohamed E.A., MacDowall P., Coward R.A. Timing of sildenafil therapy in dialysis patients-lessons following an episode of hypotension. Nephrol Dial Transplant. 2000;15(6):926-967.
  44. Solak Y., Atalay H., Kan S., Kaynar M., Bodur S., Yeksan M., Turk S. Effects of sildenafil and vardenafil treatments on sleep quality and depression in hemodialysis patients with erectile dysfunction. Int J Impot Res. 2011;23:27-31.
  45. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
  46. Shao Y.H., Demissie K., Shih W., Mehta A.R., Stein M.N., Roberts C.B., Dipaola R.S., Lu-Yao G.L. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101(18):1280-1383.
  47. Stephenson R.A., Mori M.,Hsieh Y.C., Beer T.M., Stanford J.L., Gilliland F.D., Hoffman R.M., Potosky A.L. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol. 2005;174(2):646-650.
  48. Tutolo M., Briganti A., Suardi N., Gallina A., Abdollah F., Capitanio U., Bianchi M., Passoni N., Nini A., Fossati N., Rigatti P., Montorsi F. Optimizing postoperative sexual function after radical prostatectomy. Ther Adv Urol. 2012;4(6):347-365.
  49. Salonia A., Burnett A.L., Graefen M., Hatzimouratidis K., Montorsi F., Mulhall J.P., Stief C. Prevention and management of postprostatectomy sexual dysfunctions part 1: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol. 2012;62(2):273-286.
  50. Zippe C.D., Jhaveri F.M., Klein E.A., Kedia S., Pasqualotto F.F., Kedia A., Agarwal A., Montague D.K., Lakin M.M. Role of Viagra after radical prostatectomy. Urology. 2000;55(2):241-245.
  51. Qiu S., Tang Z., Deng L., Liu L., Han P., Yang L., Wei Q. Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer. Scientific Reports. 2016;6:32853. doi: 10.1038/srep32853
  52. Deng H., Liu D., Mao X., Lan X., Liu H., Li G. Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial. Am J Mens Health. 2016 Aug 24.
  53. Goldstein I., Lurie A.L., Lubisich J.P. Bicycle riding, perineal trauma, and erectile dysfunction: data and solutions. Curr Urol Rep. 2007;8(6):491- 497.
  54. Peng J., Zhang Z., Gao B., Yuan Y., Cui W., Tang Y., Song W., Xin Z. Effect of daily sildenafil on patients with absent nocturnal erections due to pelvic fracture urethral disruption: a single-centre experience. Andrologia. 2016 Feb 9.
  55. Acevedo G.J., Varön L.F., Berbeo C.M., Feo L.O., Dias O.R. Avances fisiopatologicos para el entendimiento de la lesion medular traumatica. Revision bibliografica. Rev Col Or Tra. 2008;22:272-281.
  56. Ludwig W., Phillips M. Organic causes of erectile dysfunction in men under 40. Urol Int. 2014;92:1-6
  57. Schmid D.M., Hauri D., Schurch B. Nocturnal penile tumescence and rigidity (NPTR) findings in spinal cord injured men with erectile dysfunction. Int J. Impot Res. 2004;16:433-440.
  58. Lombardi G., Macchiarella A., Cecconi F., Del Popolo G. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. J. Sex Med. 2009;6:1248-1258.
  59. Deforge D., Blackmer J., Garritty C., Yazdi F., Cronin V., Barrowman N., Fang M., Mamaladze V., Zhang L., Sampson M., Moher D. Male erectile dysfunction following spinal cord injury: a systematic review. Spinal Cord 2006;44:465-473.
  60. Garda-Perdomo H.A., Echeverria-Garcia F., Tobias A. Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis. Urol Int. 2016 Aug 11.
  61. Bacconi L., Gressier F. Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review. Encephale. 2016; 19:S0013-7006(16)30143-9. doi: 10.1016/j. encep.2016.07.003.
  62. Schmidt H.M., Hagen M., Kriston L., Soares-Weiser K., Maayan N., Berner M.M. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev. 2012;14;11:CD003546.
  63. Taylor M.J., Rudkin L., Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. J. Affect Disord. 2005;88(3):241-254.
  64. Zajecka J., Mitchell S., Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull. 1997;33:755-760.
  65. Taylor M.J., Rudkin L., Bullemor-Day P., Lubin J., Chukwujekwu C., Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;31(5):CD003382.
  66. Li W.Q., Qureshi A.A., Robinson K.C., Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med. 2014;174(6):964-970.
  67. Lian Y., Yin H., Pollak M.N., Carrier S., Platt R.W., Suissa S., Azoulay L. Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. Eur Urol. 2016;10:S0302-2838(16)30145-142.
  68. Loeb S., Folkvaljon Y., Lambe M., Robinson D., Garmo H., Ingvar C., Stattin P. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015 ;313(24): 2449-2455.
  69. Matthews A., Langan S.M., Douglas I.J., Smeeth L., Bhaskaran K. (2016) Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: Matched Cohort Study using primary care data from the UK clinical practice research datalink. PLoS Med. 2016;13(6):e1002037.
  70. Pottegärd A., Schmidt S.A., Olesen A.B., Achacoso N., Van Den Eeden S.K., Hallas J., S0rensen H.T., Friis S., Habel L.A. Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J. Cancer. 2016;115(7):895-900.
  71. Ding G., Jiang Q., Li L., Zhang L., Zhang Z., Lu M., Li Q., Gu S., Ewing J., Chopp M. Longitudinal magnetic resonance imaging of sildenafil treatment of embolic stroke in aged rats. Stroke. 2011;42:3537-3541.
  72. Jerzak M., Kniotek M., Mrozek J., Gorski A., Baranowski W. Sildenafil citrate decreased natural killer cell activity and enhanced chance of successful pregnancy in women with a history of recurrent miscarriage. Fertil Steril. 2008;90:1848-1853.
  73. Fokas E., McKenna W.G., Muschel R.J. The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Rev. 2012;31:823-842.
  74. Magnon C., Hall S.J., Lin J., Xue X., Gerber L., Freedland S.J., Frenette P.S. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.
  75. Kim S.J., Kim J.H., Chang H.K., Kim K.H. Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy. J. Exerc Rehabil. 2016;12(3):143-147.
  76. Qian C.N., Takahashi M., Kahnoski R., Teh B.T. Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model. J. Urol. 2003;170:994-997.
  77. Chavez A.H., Scott Cofield K., Hasan Rajab M., Jo C. Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis. Asian J. Androl. 2013;15:246-248.
  78. Corona G., Rastrelli G., Burri A., Jannini E.A. Maggi M. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf. 2016;15:237-247.
  79. Gupta B.P., Murad M.H., Clifton M.M., Prokop L., Nehra A., Kopecky S.L. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med.2011;171:1797-1803.
  80. Zitzmann M., Mattern A., Hanisch J., Gooren L., Jones H., Maggi M. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1438 men. J. Sex Med. 2012;10:579-588.
  81. Isidori A.M., Buvat J., Corona G., Goldstein I., Jannini E.A., Lenzi A., Porst H., Salonia A., Traish A.M., Maggi M. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65:99-112.
  82. Guay A.T., Perez J.B., Jacobson J., Newton R.A. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J. Androl. 2001;22:793-797.
  83. Shabsigh R., Kaufman J.M., Steidle C., Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. 2008;179(5):97-102.
  84. Hatzimouratidis K., Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol. 2007;51:75-88.
  85. Jackson G., Arver S., Banks I., Stecher V.J. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks. International Journal of Clinical Practice. 2010;64(4):497-504.
  86. Gaudiano M.C., Manna L., Bartolomei M., Rodomonte A.L., Bertocchi P., Antoniella E., Romanini L., Alimonti S., Rufini L., Valvo L. Health risks related to illegal and on-line sale of drugs and food supplements: results of a survey on marketed products in Italy from 2011 to 2013. Ann Ist Super Sanita. 2016;52(1):128-132.
  87. Fayzrakhmanov N.F. Fighting trafficking of falsified and substandard medicinal products in Russia. Int J. Risk Saf Med. 2015;27(1):37-40.
  88. European Commission Tax And Customs Union. Summary of community customs activities on counterfeit and piracy. Results at the European border, 2006 http://ec.europa.eu/taxation_customs/resources/ documents/customs/customs_controls/counterfeit_piracy/statistics/ counterf_comm_2006_en.pdf
  89. Eysenbach G. Online prescribing of sildenafil (Viagra) on the World Wide Web. J. Med Internet Res. 1999;1:10.
  90. Smith K.M., Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J. Am Pharm Assoc. 2005;45:63-72.
  91. Pfizer UK. Cracking counterfeit. 2008. http://www.pfizer.co.uk/Media/ Documents/The%20Cracking%20Counterfeit%20report.pdf (January 5, 2009) Jack A. Counterfeit medicines. Bitter pills. BMJ. 2007;335: 1120-1121.
  92. Banks I. No man’s land: men, illness, and the NHS. BMJ. 2001;323:1058- 1060.
  93. Stearn D.W. Deterring the importation of counterfeit pharmaceutical products. Food Drug Law J. 2004;59:537-561.
  94. Keizers P.H., Wiegard A., Venhuis B.J. The quality of sildenafil active substance of illegal source. J. Pharm Biomed Anal. 2016;131:133-139.
  95. Kao S.L., Chan C.L., Tan B., Lim C.C., Dalan R., Gardner D., Pratt E., Lee M., Lee K.O. An unusual outbreak of hypoglycemia. N. Engl J. Med. 2009;360:734-736.
  96. Balayssac S., Trefi S., Gilard V., Malet-Martino M., Martino R., Delsuc M.A. 2D and 3D DOSY (1)H nMr, a useful tool for analysis of complex mixtures: application to herbal drugs or dietary supplements for erectile dysfunction. J Pharm Biomed Anal. 2008;50:602-612
  97. Sabucedo A.J., Gutierrez M.A., Mueller K.C., Bellissima B.L., Hsu Y.L., Rose S., Furton K.G. Sex, lies, and Niagra. JAMA. 2004;291:560-562
  98. http://www.tevapharm.com/research_development/rd_integrated/ generics/ (обращение 30.09.2016)
  99. http://www.teva.ru/news/index.php?news=4658 (обращение 30.09.2016)
  100. Камалов А.А., Осмоловский Б.Е., Охоботов Д.А., Ходырева Л.А., Тахирзаде Т.Б., Тахирзаде А.М., Геворкян А.Р. Комбинированное лечение больных эректильной дисфункцией, страдающих расстройствами мочеиспускания. Урология. 2013;3:29- 33
  101. Инструкция по применению препарата «Динамико» http://www.rlsnet.ru/tn_index_ id_47499.htm (обращение 01.11.16

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies